(7S)-BAY-593
Based on 1 Customer Validation
(7S)-BAY-593 is the S-enantiomer of BAY-593 (HY-161573). BAY-593 is an orally active GGTase-I inhibitor. BAY-593 can block YAP1/TAZ signaling in animals and has antitumor activity.
For research use only. We do not sell to patients.
- Purity : 99.61%
- CAS No.: 2413068-25-2
- Formula: C26H31F3N2O3
- Molecular Weight:476.53
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
IC50 & Target
|
YAP/TAZ-TEAD |
GGTase I |
Chemical Information
-
CAS No. 2413068-25-2
-
Appearance Solid
-
Molecular Weight 476.53
-
Formula C26H31F3N2O3
-
Color White to off-white
-
SMILES
O=C(N1CCC2(CCNC[C@]2([H])C3=CC=CC=C3OC)CC1)[C@@](OC)(C(F)(F)F)C4=CC=CC=C4
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Solvent & Solubility
In Vitro:
DMSO : 125 mg/mL (262.31 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
Purity & Documentation
-
Data Sheet (275 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.0985 mL | 10.4925 mL | 20.9850 mL | 52.4626 mL |
| 5 mM | 0.4197 mL | 2.0985 mL | 4.1970 mL | 10.4925 mL | |
| 10 mM | 0.2099 mL | 1.0493 mL | 2.0985 mL | 5.2463 mL | |
| 15 mM | 0.1399 mL | 0.6995 mL | 1.3990 mL | 3.4975 mL | |
| 20 mM | 0.1049 mL | 0.5246 mL | 1.0493 mL | 2.6231 mL | |
| 25 mM | 0.0839 mL | 0.4197 mL | 0.8394 mL | 2.0985 mL | |
| 30 mM | 0.0700 mL | 0.3498 mL | 0.6995 mL | 1.7488 mL | |
| 40 mM | 0.0525 mL | 0.2623 mL | 0.5246 mL | 1.3116 mL | |
| 50 mM | 0.0420 mL | 0.2099 mL | 0.4197 mL | 1.0493 mL | |
| 60 mM | 0.0350 mL | 0.1749 mL | 0.3498 mL | 0.8744 mL | |
| 80 mM | 0.0262 mL | 0.1312 mL | 0.2623 mL | 0.6558 mL | |
| 100 mM | 0.0210 mL | 0.1049 mL | 0.2099 mL | 0.5246 mL |
(7S)-BAY-593 Related Classifications
HY-161573A Related Classifications
Powered by Bioz